Bausch Health Co. Inc. (BHC) Announces New Data on the Cost Impact of Opioid-Induced Constipation Treatment, Including Salix’s RELISTOR

0

Enter Wall Street with StreetInsider Premium. Claim your one week free trial here.


Bausch Health Companies Inc. (NYSE: BHC) and its gastroenterology business, Salix Pharmaceuticals (“Salix”), one of the world’s largest specialty pharmaceutical companies committed to the prevention and treatment of gastrointestinal diseases, today announced that Advances in Therapy published new health economics research and findings revealing that patients who received U.S. Food and Drug Administration (FDA)-approved prescription medications for opioid-induced constipation (OIC- Rx), including RELISTOR® (SC) (methylnaltrexone bromide) subcutaneous injection, in the emergency department (ED) were less likely to be hospitalized and, when hospitalized, had a longer length of stay shorter than patients who did not receive OIC-Rx in the ED. These results highlight the potential of RELISTOR SC to provide relief to patients with CIO. In this study, data showed that OIC prescription drugs “can reduce the need for long and costly hospital stays and lead to significant improvements in the quality of patient care and outcomes.”

“ER visits and hospitalizations are significantly higher for patients who take opioids to manage chronic pain from serious conditions like cancer and who have OIC,” said lead author and director of research at Baylor College of Medicine. “This research provides significant evidence to support the use of prescription medications, including RELISTOR SC, in the treatment of OIC to potentially reduce healthcare costs and improve patient care.”

Entitled “Opioid-Induced Constipation: Impact on Emergency Department Approved Drug Costs“, this retrospective research on real-world health economics and outcomes identified more than 30,000 adult patients with OIC during an ED encounter from a large database of in-hospital encounters (2016-2019).Patients were categorized into two mutually exclusive cohorts – the OIC-Rx cohort (n=11,135) and the No OIC-Rx cohort (n=21,474) – based on whether whether or not they received an OIC-Rx in the emergency department More than 90% of the OIC-Rx cohort received RELISTOR SC Health care resource utilization and costs were measured and compared during the encounter at the emergency (with or without hospitalization), as well as during the 30-day period following discharge.

After adjusting for potential confounders, the study found that patients in the OIC-Rx cohort had a 64% reduced likelihood of being hospitalized compared to the No OIC-Rx cohort (hospitalization rate: 11 % versus 26%;p

Opioids are effective pain relievers widely used to manage different types of pain, including cancer pain and chronic non-cancer pain. Constipation is the most common complication of opioid use which not only reduces patients’ quality of life but can also lead to serious medical sequelae and psychological distress. The objective of this study was to assess the effectiveness of FDA-approved OIC-Rx – largely driven by RELISTOR SC (93%) – and their impact on hospitalizations and healthcare costs following of an emergency encounter in adult patients with OIC.

The results of the study should be interpreted in the context of certain limitations. The study was limited to the clinical information available in the database at the meetings of the hospital systems that contributed to the database; thus, measures of effectiveness (e.g., validated instrument scores, physician ratings of symptom improvement), safety (e.g., adverse event reporting), reasons patients receive whether or not OIC-Rx in the emergency department and information outside of the encounter level (eg, over-the-counter laxatives, outpatient management) could not be assessed.

This study was funded by Bausch Health US, LLC; RELISTOR SC is distributed in the United States by Salix Pharmaceuticals, which is a division of Bausch Health US, LLC. The study sponsor was involved in several aspects of the research, including study design, data interpretation, and poster production.

Share.

Comments are closed.